Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06824441 · ClinicalTrials.gov registry record · NA

Feasibility Usability & Acceptability Study: Symptom Reporting by Children Adolescents & Young Adults w/Cancer

A NA study of Pediatric Cancer and Adolescent Behavior, sponsored by Stanford University.

Active
Registry status
NA
Development phase
83
Enrollment target
1
Study location

NCT06824441: Active NA study of Pediatric Cancer and Adolescent Behavior, sponsored by Stanford University.

NCT06824441 is a NA study of Pediatric Cancer and Adolescent Behavior that is active but no longer recruiting, run by Stanford University. The registered enrollment target is 83 participants, below the 1,489-participant average among 51 other Pediatric Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06824441, a NA study of Pediatric Cancer and Adolescent Behavior, is active but no longer recruiting, sponsored by Stanford University.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
83 participants
Enrollment target
1
Study location

Study Summary

The purpose of this project is to pilot test an electronically delivered symptom assessment tool Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (Ped-PRO-CTCAE), completed by children/adolescents and young adults (AYAs) and caregivers and shared with their clinicians during an outpatient clinic visit, in preparation for a future test of intervention efficacy.

Primary Outcome

To determine the feasibility of providing clinicians with child/AYA and caregiver (proxy) subjective symptom reports using the validated Ped-PRO-CTCAE items during a clinic visit.

Interventions

  • BEHAVIORAL Age- and Role-Specific Questionnaire Administration

Study Locations (1)

California

  • Stanford University - Palo Alto

Trial Details

FieldValue
Enrollment Target 83 participants
Start Date 2024-08-18
Est. Completion 2026-10
Phase NA
Stanford University

1,744 total trials

What the registry record for NCT06824441 still lists

NCT06824441 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 1,489-participant average among 51 other Pediatric Cancer trials with a reported enrollment target (94% lower).

The record links to 3 conditions, with Pediatric Cancer appearing as the primary indexed condition, and to 1 intervention - of which Age- and Role-Specific Questionnaire Administration is the first listed.

NCT06824441 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06824441 about?

NCT06824441 is a clinical study titled "Feasibility Usability & Acceptability Study: Symptom Reporting by Children Adolescents & Young Adults w/Cancer". The purpose of this project is to pilot test an electronically delivered symptom assessment tool Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (Ped-PRO-CTCAE), completed by children/adolescents and young adults (AYAs) and caregivers and shared with...

What is the current status of trial NCT06824441?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 83 participants. The study started on 2024-08-18. Estimated completion is 2026-10.

What conditions does trial NCT06824441 study?

This clinical trial studies the following conditions: Pediatric Cancer, Adolescent Behavior, Oncology.

What interventions are being tested in trial NCT06824441?

The interventions under investigation include: Age- and Role-Specific Questionnaire Administration (BEHAVIORAL).

Who is sponsoring clinical trial NCT06824441?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06824441 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pediatric Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06824441's enrollment target sits among peer trials

83 20th of 51 higher than 32 of 51 other Pediatric Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pediatric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02974647 · 83 participants · Phase 2

    Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

  • NCT03919292 · 83 participants · Phase 1

    Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

  • NCT04626674 · 83 participants · Phase 1

    A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

  • NCT05277168 · 83 participants · Phase 1

    A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06824441, the US trial registry maintained by the National Library of Medicine. NCT06824441 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.